FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment

Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.

Jan 21, 2025 - 06:00
 0  4
FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment
Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.